I follow it and IMO they are wasting money with SYNB1891 for oncology using STING pathway. SYNB1618 for treatment of PKU is OK to pursue.
They are throwing mud at the wall and see what sticks but it costs a lot of money and it seems difficult to get more in this environment. No position, too speculative to my taste.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.